Answers are grounded in this paper and cite their sources.
A case-case-control investigation (N = 255 patients) explored the epidemiology of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Recent exposure to carbapenems and a rapidly fatal condition should prompt practitioners to shorten delays in initiating appropriate therapy, which can adversely impact CRPA outcomes, as opposed to the isolated impact of the carbapenem resistance determinant.
No takes yet. Share an insight, caveat, or question.
Aviv et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: